Source comparison
Using CJC-1295 for Fat Loss Research Evidence: [Study Design] Comparison
JCEM Phase II (abdominal obesity) 90 mcg/kg 2×/week 12 weeks Maintenance −10%, 1.6g/kg protein 11.3% (DEXA) 3.1% body fat +2.4 kg Statistically significant fat loss in controlled deficit. No effect in free-living subgroup Peptides rodent model 60 mcg/kg 2×/wee
This comparison does not assign a generated winner or score.
- JCEM Phase II (abdominal obesity)
- 90 mcg/kg 2×/week
- 12 weeks
- Maintenance −10%, 1.6g/kg protein
- 11.3% (DEXA)
- 3.1% body fat
- +2.4 kg
- Statistically significant fat loss in controlled deficit. No effect in free-living subgroup
- Peptides rodent model
- 60 mcg/kg 2×/week
- 8 weeks
- Ad libitum feeding
- 0% (not measured separately)
- No significant change
- +1.1 kg
- GH elevation confirmed, no fat loss without caloric restriction
- Endocrine Reviews (CJC + GHRP-2)
- 60 mcg/kg + 1 mcg/kg daily
- Maintenance calories, 2.0g/kg protein
- 8.7% (MRI)
- 2.4% body fat
- +1.8 kg
- Synergistic GH release, moderate fat loss with protein-focused diet
- JCEM healthy adults
- 30 mcg/kg 1×/week
- 16 weeks
- No dietary intervention
- 1.8% (not significant)
- +0.6 kg
- Low-dose protocol produced GH elevation but insufficient to trigger measurable lipolysis
- The comparison reveals a pattern: using CJC-1295 for fat loss research evidence consistently shows positive outcomes when paired with structured dietary protocols emphasizing protein adequacy and slight caloric deficits. Trials without dietary controls show GH elevation without proportional fat loss. The peptide activates the pathway, but metabolic context determines whether fat oxidation occurs.